GO:0003990 acetylcholinesterase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0003990 acetylcholinesterase activity is a molecular function defined as the catalysis of the reaction acetylcholine + H2O = choline + acetate.
• Acetylcholinesterase (AChE) terminates cholinergic neurotransmission by rapidly hydrolyzing acetylcholine in the synaptic cleft and at neuromuscular junctions.
• AChE is a serine hydrolase; its catalytic triad (Ser203, His447, Glu334 in human AChE) mediates a two-step acetylation-deacetylation mechanism.
• AChE is the primary target of organophosphate and carbamate insecticides and of symptomatic drugs for Alzheimer disease such as donepezil, rivastigmine, and galantamine.
• Human erythrocyte AChE activity is a recognized biomarker of exposure to anticholinesterase agents and is altered in several hematological and neurological conditions.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models enable causal dissection of AChE function in neurons, muscle, and immune cells.
Description
Acetylcholinesterase (AChE; EC 3.1.1.7) is a serine hydrolase that catalyzes the hydrolysis of the neurotransmitter acetylcholine into choline and acetate, a reaction formally described by the Gene Ontology term GO:0003990 acetylcholinesterase activity. This enzymatic activity is essential for terminating cholinergic signaling at synapses, neuromuscular junctions, and in the autonomic nervous system, and it is one of the most rapidly acting enzymes known, operating near the diffusion limit. Because of its central role in cholinergic transmission, AChE is a major pharmacological target: inhibitors of AChE are used to treat Alzheimer disease and myasthenia gravis, while organophosphate and carbamate pesticides exert their toxicity largely through AChE inhibition. Beyond neurotransmission, AChE activity is expressed in erythrocytes, where it serves as a peripheral biomarker of enzyme exposure and systemic cholinergic status. The enzyme has also been implicated in non-neuronal contexts, including immune regulation and airway smooth muscle function, where altered AChE activity has been observed in sensitized animal models. Researchers study GO:0003990 to understand cholinergic signaling, to develop and validate inhibitors, and to model diseases ranging from neurodegeneration to pesticide poisoning. The availability of recombinant human AChE and sensitive spectroscopic and electrometric assays has made it feasible to screen large compound libraries and to quantify enzyme activity in complex biological samples.
acetylcholinesterase activity At A Glance
| GO ID | GO:0003990 |
|---|---|
| GO term | acetylcholinesterase activity |
| Ontology | molecular_function |
| Definition | Catalysis of the reaction: acetylcholine + H2O = choline + acetate. |
| Synonyms | AcCholE; acetylcholine acetylhydrolase activity; acetylcholine hydrolase activity; acetylthiocholinesterase activity; choline esterase I activity; true cholinesterase activity |
| Major function | Termination of cholinergic neurotransmission by hydrolyzing acetylcholine in the synaptic cleft and at neuromuscular junctions. |
| Enzyme class | Serine hydrolase (EC 3.1.1.7) |
| Substrate | Acetylcholine (also hydrolyzes acetylthiocholine in vitro) |
| Products | Choline and acetate |
| Cellular location | Synaptic cleft, neuromuscular junction, erythrocyte membrane, and other cholinergic sites |
| Inhibitors | Organophosphates, carbamates, donepezil, rivastigmine, galantamine, and bis-amiridines |
What Is GO:0003990?
GO:0003990 acetylcholinesterase activity is defined by the Gene Ontology as the catalysis of the reaction acetylcholine + H2O = choline + acetate. In other words, it is the molecular function of an enzyme that hydrolyzes the ester bond of acetylcholine, releasing choline and acetate. This activity is synonymous with acetylcholine acetylhydrolase, true cholinesterase, and choline esterase I activity, and it is distinct from butyrylcholinesterase (BChE) activity, which prefers butyrylcholine as substrate.
Why Is acetylcholinesterase activity Important in Cell Biology?
GO:0003990 acetylcholinesterase activity is critically important because it controls the duration and amplitude of cholinergic signaling, and its dysregulation or inhibition leads to cholinergic crisis, neurodegeneration, and altered immune and airway responses. AChE is the target of major classes of insecticides and of the most widely prescribed symptomatic treatments for Alzheimer disease, making it a central node in neuropharmacology and toxicology. In clinical and environmental health, erythrocyte AChE activity is a validated biomarker of exposure to anticholinesterase agents, and reduced activity in airway smooth muscle has been linked to immune sensitization. The enzyme is also a model system for studying enzyme kinetics, protein stability, and structure-based inhibitor design, with computational and experimental studies continually refining our understanding of its mechanism and inhibitor interactions.
• Terminates cholinergic neurotransmission at synapses and neuromuscular junctions, preventing sustained muscle contraction and neuronal overexcitation.
• Primary target of organophosphate and carbamate pesticides, whose toxicity is mediated by AChE inhibition.
• Therapeutic target for Alzheimer disease drugs such as donepezil, rivastigmine, and galantamine.
• Erythrocyte AChE activity serves as a peripheral biomarker for exposure to anticholinesterase agents and for cholinergic status.
• Altered AChE activity has been observed in airway smooth muscle after immune sensitization, linking cholinergic signaling to asthma biology.
• AChE is a serine hydrolase model for studying catalytic triads, transition-state stabilization, and covalent inhibitors.
• Recombinant human AChE enables high-throughput screening of inhibitor libraries and antipsychotic drug profiling.
• Computational studies on AChE inform structure-based drug design and prediction of inhibitor selectivity.
• AChE activity assays are used in toxicology, drug discovery, and clinical diagnostics.
• CRISPR-engineered cell and animal models allow causal testing of AChE variants and tissue-specific functions.
What Happens During acetylcholinesterase activity?
Substrate binding and orientation
In simple terms: The enzyme grabs acetylcholine and positions it for cutting.
Acetylcholine enters the active site gorge of AChE, a deep narrow channel lined by aromatic residues that guide the substrate to the catalytic triad. The quaternary ammonium group of acetylcholine interacts with Trp86 and other aromatic residues via cation-pi interactions, while the ester carbonyl is oriented toward the catalytic serine. This binding mode ensures that the ester bond is properly aligned for nucleophilic attack. Computational simulations and crystal structures have revealed that the gorge is approximately 20 Angstroms deep and that substrate entry is rate-limited by diffusion and gating residues.
Acylation step: formation of the acyl-enzyme intermediate
In simple terms: The enzyme cuts acetylcholine and temporarily holds onto the acetate part.
Once acetylcholine is bound, the catalytic triad (Ser203, His447, Glu334 in human AChE) initiates a nucleophilic attack. The hydroxyl group of Ser203 is activated by His447, which is stabilized by Glu334, leading to the formation of a tetrahedral transition state that is stabilized by the oxyanion hole (Gly121, Gly122, Ala204). The ester bond of acetylcholine is cleaved, releasing choline, and the acetate group becomes covalently attached to Ser203 as an acyl-enzyme intermediate. This acylation step is extremely rapid, contributing to the high catalytic efficiency of AChE.
Deacylation step: release of acetate and regeneration of free enzyme
In simple terms: Water comes in to release the acetate and reset the enzyme.
In the second step, a water molecule is activated by His447 and attacks the acyl-enzyme intermediate, forming a second tetrahedral transition state that collapses to release acetate and regenerate the free enzyme. This deacylation step completes the catalytic cycle and returns AChE to its resting state, ready for another round of acetylcholine hydrolysis. The overall turnover rate of AChE is among the fastest known for any enzyme, approaching the diffusion limit.
Inhibition and reactivation
In simple terms: Certain chemicals can block the enzyme, and some can be removed by reactivators.
AChE activity can be inhibited reversibly or irreversibly. Carbamates and organophosphates form covalent adducts with the catalytic serine, with organophosphates undergoing aging that makes reactivation difficult. Reversible inhibitors such as donepezil and bis-amiridines bind non-covalently within the active site gorge, competing with acetylcholine. Oximes can reactivate organophosphate-inhibited AChE if administered before aging occurs. These inhibition mechanisms are central to the pharmacology and toxicology of AChE and are studied using recombinant human enzyme and spectroscopic assays.
Key Genes Involved in GO:0003990 acetylcholinesterase activity
The following genes and proteins are directly or functionally associated with acetylcholinesterase activity (GO:0003990) and are commonly studied in cholinergic signaling, toxicology, and drug discovery.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ACHE | Encodes acetylcholinesterase, the enzyme that hydrolyzes acetylcholine | Primary gene for GO:0003990; target of inhibitors and disease mutations |
| BCHE | Encodes butyrylcholinesterase, a related esterase that hydrolyzes acetylcholine and other esters | Comparative studies on substrate specificity and inhibitor selectivity |
| CHAT | Encodes choline acetyltransferase, which synthesizes acetylcholine | Upstream of AChE in cholinergic transmission |
| SLC18A3 | Encodes vesicular acetylcholine transporter (VAChT) | Packages acetylcholine into synaptic vesicles |
| CHRNA1 | Encodes nicotinic acetylcholine receptor alpha-1 subunit | Mediates postsynaptic response to acetylcholine at neuromuscular junction |
| CHRNB1 | Encodes nicotinic acetylcholine receptor beta-1 subunit | Part of muscle-type nicotinic receptor complex |
| CHRNE | Encodes nicotinic acetylcholine receptor epsilon subunit | Adult neuromuscular junction receptor subunit |
| CHRND | Encodes nicotinic acetylcholine receptor delta subunit | Neuromuscular junction receptor subunit |
| CHRM1 | Encodes muscarinic acetylcholine receptor M1 | Mediates central and peripheral muscarinic signaling |
| CHRM2 | Encodes muscarinic acetylcholine receptor M2 | Autoreceptor that regulates acetylcholine release |
| CHRM3 | Encodes muscarinic acetylcholine receptor M3 | Smooth muscle and glandular responses to acetylcholine |
| COLQ | Encodes collagen-like tail subunit of asymmetric AChE | Anchors AChE at neuromuscular junction |
| PRIMA1 | Encodes proline-rich membrane anchor 1 | Anchors AChE to neuronal membranes |
| RAPSN | Encodes rapsyn, a postsynaptic scaffold protein | Clusters acetylcholine receptors at neuromuscular junction |
| AGRN | Encodes agrin, which organizes postsynaptic specialization | Indirectly influences AChE localization |
| LRP4 | Encodes LDL receptor-related protein 4 | Agrin co-receptor in neuromuscular junction formation |
| DOK7 | Encodes docking protein 7 | Required for neuromuscular junction maintenance |
| MUSK | Encodes muscle-specific kinase | Central to neuromuscular junction assembly and AChE anchoring |
How Is acetylcholinesterase activity Regulated?
Acetylcholinesterase activity is regulated at multiple levels. Transcriptionally, the ACHE gene produces multiple splice variants with tissue-specific expression, including the synaptic (S) and readthrough (R) forms, and its promoter responds to cholinergic and inflammatory signals. Post-translationally, AChE is glycosylated, phosphorylated, and assembled into monomers, dimers, and tetramers that are anchored to membranes via PRIMA1 or COLQ. Enzyme activity can be acutely modulated by substrate availability, pH, and endogenous inhibitors, and it is inhibited by pharmacological agents such as organophosphates, carbamates, and bis-amiridines. In disease states, AChE activity is altered by oxidative stress, amyloid-beta aggregation, and immune sensitization, as observed in airway smooth muscle after active immune sensitization. These regulatory layers make AChE a dynamic node in cholinergic physiology and a target for therapeutic intervention.
acetylcholinesterase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ACHE | Alzheimer disease; cholinergic deficit | Knockout or point-mutation in neuronal cell lines; overexpression for inhibitor screening |
| ACHE | Organophosphate poisoning; biomarker of exposure | Erythrocyte-like cell models with tagged AChE for activity assays |
| COLQ | Congenital myasthenic syndrome | Knock-in of patient mutations in muscle cell lines or animal models |
| BCHE | Altered drug metabolism; butyrylcholinesterase deficiency | Knockout and overexpression in hepatocyte-like cells |
| CHRNA1 | Myasthenia gravis; congenital myasthenic syndrome | Point-mutation knock-in in muscle cells to study receptor function |
Alzheimer disease and cholinergic deficit
Alzheimer disease is characterized by loss of cholinergic neurons in the basal forebrain and reduced acetylcholine levels, which has motivated the use of AChE inhibitors as symptomatic therapy. Donepezil, rivastigmine, and galantamine inhibit AChE activity and temporarily improve cognitive symptoms. Bis-amiridines have been developed as multitarget AChE and BChE inhibitors with additional anti-amyloid properties, illustrating the ongoing effort to optimize inhibitor profiles for Alzheimer disease. Computational studies on AChE structure have guided the design of these inhibitors and helped predict their binding modes.
Organophosphate and carbamate toxicity
Organophosphate and carbamate pesticides and nerve agents exert their acute toxicity by inhibiting AChE, leading to accumulation of acetylcholine at synapses and neuromuscular junctions, which causes cholinergic crisis with miosis, salivation, bronchoconstriction, fasciculations, and respiratory failure. Erythrocyte AChE activity is widely used as a biomarker of exposure, and its measurement in clinical and environmental toxicology relies on sensitive spectroscopic and electrometric assays. Reactivation of inhibited enzyme by oximes is time-dependent and limited by aging of the organophosphate-enzyme adduct.
Neuromuscular junction disorders
Congenital myasthenic syndromes can result from mutations in genes that anchor AChE at the neuromuscular junction, such as COLQ, leading to prolonged acetylcholine action and impaired neuromuscular transmission. Autoimmune myasthenia gravis targets acetylcholine receptors and associated proteins, and AChE inhibitors are used to improve muscle strength. The precise localization and activity of AChE are therefore critical for normal neuromuscular function, and animal models with altered AChE anchoring have been used to study these disorders.
Airway hyperresponsiveness and immune sensitization
Reduced AChE activity has been observed in canine tracheal smooth muscle homogenates after active immune sensitization, suggesting that cholinergic signaling may contribute to airway hyperresponsiveness in allergic asthma. This finding links AChE regulation to immune-mediated airway disease and supports further investigation of cholinergic mechanisms in asthma and chronic obstructive pulmonary disease.
From acetylcholinesterase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of AChE activity alter cholinergic signaling? | ACHE knockout cell line (e.g., SH-SY5Y or HEK293) with rescue |
| How do disease-associated ACHE mutations affect catalytic activity? | Point-mutation knock-in of specific variants followed by enzyme activity assay |
| Can a candidate inhibitor selectively target AChE over BChE? | Overexpression of recombinant human ACHE and BCHE in HEK293 cells for screening |
| Where is AChE localized in neurons and muscle? | Tagged knock-in of ACHE with fluorescent protein for imaging |
| Does AChE anchoring affect neuromuscular junction stability? | COLQ or PRIMA1 knockout in muscle cell models |
| What is the effect of AChE overexpression on cell survival? | Doxycycline-inducible ACHE overexpression in neuronal cell lines |
How to Study the acetylcholinesterase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Ellman assay | AChE-catalyzed hydrolysis of acetylthiocholine | Inhibitor screening; erythrocyte AChE activity |
| Electrometric assay | pH change from acetate release | Validation of AChE activity in samples with colored compounds |
| Recombinant expression | Production of active human AChE | Structural studies; high-throughput screening |
| Molecular docking | Predicted binding poses of inhibitors | Structure-based drug design |
| Immunohistochemistry | Tissue and cellular localization of AChE | Neuromuscular junction and brain studies |
| Fluorescent tagging | Real-time trafficking and anchoring | Live-cell imaging of AChE dynamics |
| CRISPR knockout | Loss-of-function phenotype | Causal testing of AChE in cholinergic signaling |
| CRISPR knock-in | Expression of mutant or tagged AChE | Disease variant modeling and localization |
Enzymatic activity assays
AChE activity is most commonly measured using the Ellman assay, which couples the hydrolysis of acetylthiocholine to the reduction of DTNB and monitors the formation of a yellow thiolate anion at 412 nm. Electrometric techniques measure the pH change associated with acetate release and offer an alternative for samples with interfering chromophores. These assays are used to screen inhibitors, quantify enzyme in biological samples, and assess exposure to anticholinesterase agents.
Recombinant protein expression and purification
Recombinant human AChE can be expressed in mammalian cells or in bacteria after engineering for stability and solubility. Automated structure- and sequence-based design has been used to improve bacterial expression of AChE, enabling high-yield production for structural and kinetic studies. Purified enzyme is used in inhibition assays, crystallography, and computational docking studies.
Computational modeling and docking
Molecular dynamics simulations and docking studies provide atomic-level insights into substrate binding, catalytic mechanism, and inhibitor interactions within the AChE active site gorge. These computational approaches complement experimental assays and guide the design of novel inhibitors with improved selectivity and pharmacokinetic properties.
Cell-based imaging and localization
Fluorescently tagged AChE or immunohistochemistry can reveal the subcellular localization of the enzyme in neurons, muscle, and erythrocytes. Tagged knock-in models allow real-time tracking of AChE trafficking and anchoring at the neuromuscular junction and synapses, providing spatial context for activity measurements.
How CRISPR Can Be Used to Study GO:0003990 acetylcholinesterase activity
Knockout
CRISPR-Cas9 knockout of ACHE in neuronal or muscle cell lines eliminates acetylcholinesterase activity, leading to acetylcholine accumulation and altered cholinergic signaling. These models are used to test whether AChE is required for specific physiological responses and to identify compensatory mechanisms. Knockout of COLQ or PRIMA1 can disrupt AChE anchoring and mimic congenital myasthenic syndromes.
Point Mutation
Point mutations in ACHE that alter catalytic residues or inhibitor-binding sites can be introduced by CRISPR base editing or homology-directed repair. These models help determine how specific residues contribute to catalysis, substrate specificity, and inhibitor sensitivity. For example, mutations in the catalytic triad or oxyanion hole reduce enzyme activity and can be compared with wild-type enzyme in kinetic assays.
Knock-in
Knock-in of tagged ACHE (e.g., GFP or HA) allows visualization and immunoprecipitation of the enzyme in its native context. Knock-in of disease-associated variants, such as those affecting glycosylation or anchoring, provides models for studying congenital myasthenic syndromes and other cholinergic disorders. These models are also useful for validating antibody specificity and for proximity labeling studies.
Overexpression
Overexpression of ACHE in cell lines or animal models can be achieved by CRISPR activation or by lentiviral delivery. Overexpression models are used to screen inhibitors, study the effects of excess AChE on cell survival and synaptic function, and produce recombinant enzyme for structural studies. Inducible overexpression systems allow temporal control of AChE levels and avoid developmental compensation.
How EDITGENE Supports acetylcholinesterase activity Research
Researchers studying acetylcholinesterase activity-related genes often need to determine whether a candidate gene is causally involved in cholinergic signaling, inhibitor response, or disease phenotypes. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models that enable such causal experiments, from complete knockout to subtle point mutations and tagged knock-ins.
Contact EDITGENE today to design your custom CRISPR model for acetylcholinesterase activity research.
Frequently Asked Questions About acetylcholinesterase activity
What is acetylcholinesterase activity?
Acetylcholinesterase activity (GO:0003990) is the catalysis of the reaction acetylcholine + H2O = choline + acetate, which terminates cholinergic neurotransmission.
What genes are involved in acetylcholinesterase activity?
The primary gene is ACHE, which encodes acetylcholinesterase. Related genes include BCHE, CHAT, SLC18A3, CHRNA1, CHRM1, COLQ, and PRIMA1, which contribute to cholinergic signaling and AChE anchoring.
What is the GO ID for acetylcholinesterase activity?
The Gene Ontology ID for acetylcholinesterase activity is GO:0003990, classified under molecular_function.
How is acetylcholinesterase activity measured?
It is commonly measured using the Ellman assay with acetylthiocholine as substrate, or by electrometric methods that detect acetate release.
What diseases are associated with altered acetylcholinesterase activity?
Altered AChE activity is associated with Alzheimer disease, organophosphate poisoning, congenital myasthenic syndromes, and airway hyperresponsiveness.
What drugs inhibit acetylcholinesterase?
Donepezil, rivastigmine, galantamine, carbamates, organophosphates, and bis-amiridines are known AChE inhibitors.
Can CRISPR be used to study acetylcholinesterase activity?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of ACHE and related genes in cholinergic signaling and disease.
What is the difference between AChE and BChE?
AChE (GO:0003990) preferentially hydrolyzes acetylcholine and is the primary enzyme at synapses, while BChE has broader substrate specificity and is found in plasma and other tissues.
Why is erythrocyte AChE activity important?
Erythrocyte AChE activity serves as a peripheral biomarker of exposure to anticholinesterase agents and reflects systemic cholinergic status.
How does organophosphate poisoning affect AChE?
Organophosphates covalently inhibit AChE by phosphorylating the catalytic serine, leading to acetylcholine accumulation and cholinergic crisis.
Conclusion
GO:0003990 acetylcholinesterase activity is a fundamental molecular function that controls cholinergic signaling by hydrolyzing acetylcholine into choline and acetate. Its central role in neurotransmission, neuromuscular junction function, and toxicology makes it a key target for drug discovery and a model enzyme for mechanistic studies. Dysregulation or inhibition of AChE activity underlies Alzheimer disease, organophosphate poisoning, congenital myasthenic syndromes, and airway hyperresponsiveness, highlighting its clinical and environmental health relevance. Advances in recombinant enzyme production, computational modeling, and CRISPR-based genome editing continue to deepen our understanding of AChE biology and to enable the development of safer and more selective inhibitors.
References
- 1. Azman NAN et al.. 2020. Potential Anti-Acetylcholinesterase Activity of Cassia timorensis DC.. Molecules 25(19) PMID: 33020403
- 2. Obara K et al.. 2019. Inhibition of Recombinant Human Acetylcholinesterase Activity by Antipsychotics.. Pharmacology 104(1-2):43-50 PMID: 31067549
- 3. Goldenzweig A et al.. 2016. Automated Structure- and Sequence-Based Design of Proteins for High Bacterial Expression and Stability.. Mol Cell 63(2):337-346 PMID: 27425410
- 4. Makhaeva GF et al.. 2022. Bis-Amiridines as Acetylcholinesterase and Butyrylcholinesterase Inhibitors: N-Functionalization Determines the Multitarget Anti-Alzheimer's Activity Profile.. Molecules 27(3) PMID: 35164325
- 5. Xu Y et al.. 2017. Computational Studies on Acetylcholinesterases.. Molecules 22(8) PMID: 28796192
- 6. Costa BF et al.. 2026. Comparative screening of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) activity using spectroscopic and electrometric techniques.. Toxicol Mech Methods 36(4):515-526 PMID: 41748329
- 7. Saldanha C. 2017. Human Erythrocyte Acetylcholinesterase in Health and Disease.. Molecules 22(9) PMID: 28885588
- 8. Mitchell RW et al.. 1991. Reduced activity of acetylcholinesterase in canine tracheal smooth muscle homogenates after active immune-sensitization.. Am J Respir Cell Mol Biol 5(1):56-62 PMID: 1908687
